The ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) shows superior mid-cap dividend growth with a 7.00% five-year CAGR, outperforming the large-cap NOBL ETF. REGL's sector focus on Financials (31.2%) offers a distinct advantage over NOBL's heavy Consumer Staples exposure, resulting in more attractive price-to-earnings ratios. The ETF also demonstrates better earnings per share growth, suggesting that REGL's 15-year dividend growth requirement is more effective than NOBL's 25-year rule. The analyst maintains a preference for REGL over NOBL, with current ratings of “hold” and “sell” respectively, highlighting REGL's stability and downside protection.
The ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) is highlighted with a 7.00% five-year dividend CAGR, noted for its superior mid-cap dividend growth. For readers following Financials-sector US stocks on Pluang, here is the market snapshot as of Oct 19, 2026 16:11 WIB: out of 142 priced stocks, 65 rose and 34 fell. Notable movers include CLSK at USD 8.61 (+2.50%), PSEC at USD 1.64 (+2.50%), and HDB at USD 23.26 (-2.43%).
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
